- Overview of HCC treatment
- How immune checkpoint inhibitors fit into the treatment landscape for advanced HCC
- Key data in the first-line and second-line settings
- Practical guidance
- Key patient considerations for treatment with immune checkpoint inhibitors (including cirrhosis, HBV/HCV status)
- Managing key immune-related adverse events
- Best practices in multidisciplinary care
- Final thoughts and audience question and answer session
Register at: http://www.clinicaloptions.com/HCCHepatologyWebinarsJoin2
Date / Time
The goal of this activity is to improve the knowledge, confidence, and competence of learners in their clinical use of optimal HCC immunotherapy options.
This program is intended for hepatologists and other healthcare providers who care for patients with HCC.
Upon completion of this activity, participants should be able to:
- Identify patients with HCC most likely to benefit from immune checkpoint inhibitor–based combination therapy based on tumor characteristics, previous treatment, comorbid liver diseases, and patient characteristics and preferences
- Review recent therapeutic advances and FDA approvals for the use of immune checkpoint inhibitor–based treatment approaches for patients with early or intermediate-stage HCC
- Plan optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
- Evaluate clinical data on the use of novel systemic for patients with relapsed/refractory advanced HCC and integrate this information into clinical practice, taking into consideration the available clinical evidence, preexisting cirrhosis and other liver diseases, known agent toxicity/ tolerability profiles, expert recommendations, and patient preferences
- Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitor therapy in patients with HCC, while also managing comorbid liver diseases
- Plan strategies and care plans for coordination of treatment of HCC to maximize benefit for local and systemic therapies.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-073-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.